The University of Washington’s Memory and Brain Wellness Center at Harborview Medical Center has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive ...

A new medication called donanemab appears to slow memory loss, giving patients the gift of more time. UW Medicine's Memory & Brain Wellness Center at Harborview Medical Center recently started ...

Donanemab, made by Eli Lilly and sold under the brand name Kisunla, is not a cure, nor can it reverse memory loss, doctors say. But research has shown that, like its predecessor lecanemab ...

Since then, other amyloid-targeting monoclonal antibodies, lecanemab and donanemab, have been approved by the US Food and Drug Administration (FDA) for early Alzheimer’s disease. 3 Importantly ...

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of ...

The Mini-Mental State Examination (MMSE) continues to be the most widely used screening instrument for Alzheimer's disease (AD). However, the test has been criticized along several lines ...

2-Year U.S. Treasury Note Continuous Contract $103.918-0.043-0.04% 5-Year U.S. Treasury Note Continuous Contract $108.820-0.109-0.10% 10-Year U.S. Treasury Note Continuous Contract $111.766-0.141 ...

Four years ago, the Skaneateles Central School District began a club as students found interest in discussing and supporting mental health among their peers. The club, which became an official ...

2-Year U.S. Treasury Note Continuous Contract $104.016 0.055 0.05% 5-Year U.S. Treasury Note Continuous Contract $109.109 0.180 0.16% 10-Year U.S. Treasury Note Continuous Contract $112.188 0.281 ...

If approved, it could provide an alternative to lecanemab (recently approved for a subgroup of patients with Alzheimer’s disease) and donanemab (which was rejected in Europe in March 2025 due to ...